These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23104837)

  • 1. Statistical learning confirms the diagnostic significance of the anemia panel in breast cancer.
    Biljan M; Dmitrović B; Kristek J; Šimundić AM; Mandić S; Šerić V; Margaretić D; Debeljak Ž
    Clin Chem Lab Med; 2012; 50(9):1671-8. PubMed ID: 23104837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
    Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
    Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tissue polypeptide antigen (TPA) with cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Distler W
    Clin Chem Lab Med; 1998 Nov; 36(11):841-6. PubMed ID: 9877089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.
    Hermann N; Dressen K; Schroeder L; Debald M; Schildberg FA; Walgenbach-Bruenagel G; Hettwer K; Uhlig S; Kuhn W; Hartmann G; Holdenrieder S
    Tumour Biol; 2017 Jun; 39(6):1010428317711381. PubMed ID: 28618926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
    Ławicki S; Zajkowska M; Głażewska EK; Będkowska GE; Szmitkowski M
    Clin Lab; 2016 Sep; 62(9):1661-1669. PubMed ID: 28164586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer.
    Sütterlin M; Bussen S; Trott S; Caffier H
    Anticancer Res; 1999; 19(4A):2567-70. PubMed ID: 10470196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
    Knychalski B; Lukieńczuk T
    Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
    Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
    Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer.
    Sliwowska I; Kopczyński Z; Grodecka-Gazdecka S
    Postepy Hig Med Dosw (Online); 2006; 60():295-9. PubMed ID: 16767053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast.
    Lee A; Kim Y; Han K; Kang CS; Jeon HM; Shim SI
    Arch Pathol Lab Med; 2004 Nov; 128(11):1251-6. PubMed ID: 15508191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of cancer antigen, CA 15.3 in breast cancer.
    Muthuswamy S; Raste AS
    Indian J Med Sci; 2000 Oct; 54(10):442-7. PubMed ID: 11262861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.